Oculeve, a subsidiary of Allergan, specializes in developing innovative treatments for dry eye disease through advanced neurostimulation technology. The company primarily serves patients suffering from chronic dry eye conditions, a prevalent issue in the ophthalmology market. Oculeve operates within the healthcare sector, focusing on medical devices and therapeutic solutions. Its business model revolves around the research, development, and commercialization of its proprietary neurostimulation devices, which are designed to stimulate the lacrimal gland and increase tear production. Revenue is generated through the sale of these medical devices to healthcare providers and directly to patients. The company leverages its strong R&D capabilities and strategic partnerships to maintain a competitive edge in the market.

Keywords: dry eye disease, neurostimulation, ophthalmology, medical devices, lacrimal gland, tear production, healthcare, therapeutic solutions, R&D, commercialization.